Shinobi Therapeutics

📍 South San Francisco, United States🗓 Founded 2023👥 31 employees💰 Last funded Dec 2023
Biotechnology Research🌐 shinobitx.com
Website LinkedIn
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Shinobi Therapeutics?
Shinobi Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Shinobi Therapeutics last raise funding?
The most recent investment in Shinobi Therapeutics recorded on gritt.io was in December 2023.
When was Shinobi Therapeutics founded?
Shinobi Therapeutics was founded in 2023.
What industry is Shinobi Therapeutics in?
Shinobi Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Shinobi Therapeutics based?
Shinobi Therapeutics is headquartered in South San Francisco, United States.